155 related articles for article (PubMed ID: 36450003)
1. Disease progression model using the integrated Alzheimer's Disease Rating Scale.
Gueorguieva I; Chua L; Willis BA; Sims JR; Wessels AM
Alzheimers Dement; 2023 Jun; 19(6):2253-2264. PubMed ID: 36450003
[TBL] [Abstract][Full Text] [Related]
2. Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.
Wessels AM; Belger M; Johnston JA; Yu Y; Rentz DM; Dowsett SA; Chandler J
J Alzheimers Dis; 2022; 88(2):577-588. PubMed ID: 35694928
[TBL] [Abstract][Full Text] [Related]
3. Minimal clinically important difference in Alzheimer's disease: Rapid review.
Muir RT; Hill MD; Black SE; Smith EE
Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
[TBL] [Abstract][Full Text] [Related]
4. The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial.
Wessels AM; Andersen SW; Dowsett SA; Siemers ER
J Prev Alzheimers Dis; 2018; 5(2):134-136. PubMed ID: 29616706
[TBL] [Abstract][Full Text] [Related]
5. Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates.
Wessels AM; Rentz DM; Case M; Lauzon S; Sims JR
Alzheimers Dement (N Y); 2022; 8(1):e12312. PubMed ID: 35676941
[TBL] [Abstract][Full Text] [Related]
6. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).
Wessels AM; Siemers ER; Yu P; Andersen SW; Holdridge KC; Sims JR; Sundell K; Stern Y; Rentz DM; Dubois B; Jones RW; Cummings J; Aisen PS
J Prev Alzheimers Dis; 2015 Dec; 2(4):227-241. PubMed ID: 27019841
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
[TBL] [Abstract][Full Text] [Related]
8. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
9. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
11. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
[TBL] [Abstract][Full Text] [Related]
12. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.
Lansdall CJ; McDougall F; Butler LM; Delmar P; Pross N; Qin S; McLeod L; Zhou X; Kerchner GA; Doody RS
J Prev Alzheimers Dis; 2023; 10(1):9-18. PubMed ID: 36641605
[TBL] [Abstract][Full Text] [Related]
13. Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years.
Darmanthé N; Tabatabaei-Jafari H; Cherbuin N;
J Alzheimers Dis; 2021; 82(3):951-964. PubMed ID: 34120902
[TBL] [Abstract][Full Text] [Related]
14. Souvenaid for Alzheimer's disease.
Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
[TBL] [Abstract][Full Text] [Related]
15. Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Wessels AM; Dennehy EB; Dowsett SA; Dickson SP; Hendrix SB
Neurol Clin Pract; 2023 Apr; 13(2):e200127. PubMed ID: 36891463
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Isaac MG; Clark AR; Rusted J; Tabet N
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD002854. PubMed ID: 23152215
[TBL] [Abstract][Full Text] [Related]
17. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
Sato S; Hatakeyama N; Fujikoshi S; Katayama S; Katagiri H; Sims JR
Neurol Ther; 2024 Jun; 13(3):677-695. PubMed ID: 38581616
[TBL] [Abstract][Full Text] [Related]
18. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.
Suzuki K; Hirakawa A; Ihara R; Iwata A; Ishii K; Ikeuchi T; Sun CK; Donohue M; Iwatsubo T;
Alzheimers Dement (N Y); 2020; 6(1):e12007. PubMed ID: 32211510
[TBL] [Abstract][Full Text] [Related]
19. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
[TBL] [Abstract][Full Text] [Related]
20. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MGEKN; Tabet N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]